First AD

Second AD

George Yaghmour, MD, and Rachel Elizabeth Rau, MD, discuss how to incorporate blinatumomab into clinical practice for ALL.

Incorporating Blinatumomab into Clinical Practice for ALL

Hematologic Oncology

The OncLive Hematology Oncology condition center page is a comprehensive resource for clinical news and expert insights on various hematologic malignancies, including leukemias, lymphomas, myeloproliferative neoplasms, multiple myeloma, and much more. This section features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in hematologic cancers.

Developments in Acute Lymphoblastic Leukemia Following ASH 2024

OncLive News Network®

USC Norris Comprehensive Cancer Center

Cancer Centers

Partner

Frontline Treatment Considerations in Adult and Pediatric Acute Lymphoblastic Leukemia

AlloHCT Outcomes From ECOG ACRIN E1910 in Newly Diagnosed, MRD-Negative B-Lineage ALL

Adding Blinatumomab to Consolidation Therapy in Older Patients With Newly Diagnosed, BCR::ABL1–Negative B-ALL

Approaching First-Line Treatment Decisions in Pediatric ALL

Blinatumomab Plus Chemo in Newly Diagnosed, Standard-Risk Pediatric B-ALL

Mitigation and Management Strategies for ICANS and Other AEs in ALL 

Ongoing Research to Watch in Acute Lymphoblastic Leukemia